Atopic Dermatitis
Conditions
Keywords
Skin barrier, Microplastics, Organophosphate Flame Retardants, OPFRs, Perfluoroalkyl and Polyfluoroalkyl Substances, PFASs, Contaminants of Emerging Concern, CECs, Emerging Contaminants, ECs, Atopic Dermatitis, Maternal, Cohort, Birth
Brief summary
This prospective cohort study aims to investigate the association between prenatal blood levels of Emerging Contaminants and the five-year incidence of atopic dermatitis (AD) in offspring.
Detailed description
This prospective birth cohort study, conducted within the Shanghai prenatal population, involves the collection of maternal blood samples during gestation to directly measure the biological exposure levels of Emerging Contaminants, including Per- and Polyfluoroalkyl Substances (PFAS), Organophosphate Flame Retardants (OPFRs), and Microplastics. Serum and whole blood levels of these contaminants are evaluated during pregnancy at 12-14, 22-26, and 31-34 gestational weeks. Subsequently, the study assesses skin barrier function in infants at 24-48 hours, 42 days, and 6 months of age. During a five-year period, the occurrence of atopic dermatitis (AD) in offspring is assessed. The objectives of this cohort study are twofold: (1) to elucidate the relationship between maternal exposure to Emerging Contaminants and the development of AD in offspring, and (2) to evaluate the impact of such exposure on the skin barrier function of infants. This research aims to provide substantial evidence for the prevention of AD, offering a unique and meaningful approach to mitigating the incidence of AD.
Interventions
OTHERGestational Exposure to Emerging Contaminants (ECs)
Levels of Emerging Contaminants (ECs), such as Per- and Polyfluoroalkyl Substances (PFASs), Organophosphate Flame Retardants (OPFRs), and Microplastics, are assessed in maternal blood and umbilical cord blood during gestation.
Sponsors
Children's Hospital of Fudan University
Minhang Maternal and Children Health Care Hospital
School of Public Health，Fudan University
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Healthy volunteers
No
Inclusion criteria
* Mother plans to proceed prenatal care and delivery in Minhang Maternal and Children Health Care Hospital * 12-14 weeks of singleton pregnancy, non-stillborn or miscarrying, offspring without familial hereditary skin diseases * Offspring plans to stay in Shanghai until 5 years and proceed follow-up at the Dermatology Department of Children's Hospital affiliated with Fudan University * signed informed consent.
Exclusion criteria
* Multiple pregnancies * perinatal death * a fetus with congenital skin or appendages disorders
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| atopic dermatitis: Infant atopic dermatitis incidence | at 1 year old | Disease diagnosis according to the criteria of Williams. Skin status was examined via onsite interview by pediatric dermatologists. Parents consulted or visited a dermatologist once their baby developed any skin symptoms. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| prenatal exposure to Microplastics at early pregnancy | 12-14 gestational weeks | Maternal whole blood levels of Microplastics |
| prenatal exposure to Microplastics at mid pregnancy | 22-26 gestational weeks | Maternal whole blood levels of Microplastics |
| prenatal exposure to Microplastics at late pregnancy | 34-36 gestational weeks | Maternal whole blood levels of Microplastics |
| prenatal exposure to Microplastics at first trimester | 12-14 gestational weeks | Maternal serum levels of Microplastics |
| prenatal exposure to Microplastics at second trimester | 22-26 gestational weeks | Maternal serum levels of Microplastics |
| prenatal exposure to Microplastics at third trimester | 34-36 gestational weeks | Maternal serum levels of Microplastics |
| Microplastics in Umbilical cord whole blood | at delivery. | Umbilical cord whole blood levels of Microplastics |
| Umbilical cord serum Microplastics | at delivery. | Umbilical cord serum levels of Microplastics |
| Allergic rhinitis | incidence of allergic rhinitis at the age of five. | An inquiry into the patient's medical history and electronic medical record |
| Asthma | incidence of asthma at the age of five. | An inquiry into the patient's medical history and electronic medical record |
| Infantile hemangioma | incidence of Infantile hemangioma at 1 year old | Diagnosed by dermatologists |
| Infant skin barrier function (sebum content) | infant 24-48 hours | Sebum content will be evaluated by the device of Multi Probe Adapter 4. |
| atopic dermatitis | incidence of AD during 6 months after birth | Disease diagnosis according to the criteria of Williams. Skin status was examined via onsite interview by pediatric dermatologists. Parents consulted or visited a dermatologist once their baby developed any skin symptoms. |
| prenatal exposure to Perfluoroalkyl and Polyfluoroalkyl Substances (PFASs) at early pregnancy | 12-14 gestational weeks | Maternal whole blood levels of Perfluoroalkyl and Polyfluoroalkyl Substances (PFASs) comprising 15 variants: PFPeA, PFHxA, PFHpA, PFOA, PFNA, PFDA, PFUnDA, PFDoDA, PFTrDA, PFHpDA, PFBS, PFPeS, PFHxS, PFOS, and PFDS |
| prenatal exposure to Perfluoroalkyl and Polyfluoroalkyl Substances (PFASs) at mid pregnancy | 22-26 gestational weeks | Maternal whole blood levels of Perfluoroalkyl and Polyfluoroalkyl Substances (PFASs) comprising 15 variants: PFPeA, PFHxA, PFHpA, PFOA, PFNA, PFDA, PFUnDA, PFDoDA, PFTrDA, PFHpDA, PFBS, PFPeS, PFHxS, PFOS, and PFDS |
| prenatal exposure to Perfluoroalkyl and Polyfluoroalkyl Substances (PFASs) at late pregnancy | 34-36 gestational weeks | Maternal whole blood levels of Perfluoroalkyl and Polyfluoroalkyl Substances (PFASs) comprising 15 variants: PFPeA, PFHxA, PFHpA, PFOA, PFNA, PFDA, PFUnDA, PFDoDA, PFTrDA, PFHpDA, PFBS, PFPeS, PFHxS, PFOS, and PFDS |
| prenatal exposure to Perfluoroalkyl and Polyfluoroalkyl Substances (PFASs) at first trimester | 12-14 gestational weeks | Maternal serum levels of Perfluoroalkyl and Polyfluoroalkyl Substances (PFASs) comprising 15 variants: PFPeA, PFHxA, PFHpA, PFOA, PFNA, PFDA, PFUnDA, PFDoDA, PFTrDA, PFHpDA, PFBS, PFPeS, PFHxS, PFOS, and PFDS |
| prenatal exposure to Perfluoroalkyl and Polyfluoroalkyl Substances (PFASs) at second trimester | 22-26 gestational weeks | Maternal serum levels of Perfluoroalkyl and Polyfluoroalkyl Substances (PFASs) comprising 15 variants: PFPeA, PFHxA, PFHpA, PFOA, PFNA, PFDA, PFUnDA, PFDoDA, PFTrDA, PFHpDA, PFBS, PFPeS, PFHxS, PFOS, and PFDS |
| prenatal exposure to Perfluoroalkyl and Polyfluoroalkyl Substances (PFASs) at third trimester | 34-36 gestational weeks | Maternal serum levels of Perfluoroalkyl and Polyfluoroalkyl Substances (PFASs) comprising 15 variants: PFPeA, PFHxA, PFHpA, PFOA, PFNA, PFDA, PFUnDA, PFDoDA, PFTrDA, PFHpDA, PFBS, PFPeS, PFHxS, PFOS, and PFDS |
| Perfluoroalkyl and Polyfluoroalkyl Substances (PFASs) in Umbilical cord whole blood | at delivery | Umbilical cord whole blood levels of PFDoDA, PFTrDA, PFHpDA, PFBS, PFPeS, PFHxS, PFOS, and PFDS |
| Umbilical cord serum Perfluoroalkyl and Polyfluoroalkyl Substances (PFASs) | at delivery. | Umbilical cord serum levels of PFDoDA, PFTrDA, PFHpDA, PFBS, PFPeS, PFHxS, PFOS, and PFDS |
| prenatal exposure to Organophosphate Flame Retardants (OPFRs) at early pregnancy | 12-14 gestational weeks | Maternal whole blood levels of Organophosphate Flame Retardants (OPFRs) comprising 9 variants: TEP、TBP、TBEP/TBOEP、TPrP、TCEP、TCPP/TCIPP、TDCPP/TDCIPP、TDBP/TDBPP、TPhP/TPHP |
| prenatal exposure to Organophosphate Flame Retardants (OPFRs) at mid pregnancy | 22-26 gestational weeks | Maternal whole blood levels of Organophosphate Flame Retardants (OPFRs) comprising 9 variants: TEP、TBP、TBEP/TBOEP、TPrP、TCEP、TCPP/TCIPP、TDCPP/TDCIPP、TDBP/TDBPP、TPhP/TPHP |
| prenatal exposure to Organophosphate Flame Retardants (OPFRs) at late pregnancy | 34-36 gestational weeks | Maternal whole blood levels of Organophosphate Flame Retardants (OPFRs) comprising 9 variants: TEP、TBP、TBEP/TBOEP、TPrP、TCEP、TCPP/TCIPP、TDCPP/TDCIPP、TDBP/TDBPP、TPhP/TPHP |
| prenatal exposure to Organophosphate Flame Retardants (OPFRs) at first trimester | 12-14 gestational weeks | Maternal serum levels of Organophosphate Flame Retardants (OPFRs) comprising 9 variants: TEP、TBP、TBEP/TBOEP、TPrP、TCEP、TCPP/TCIPP、TDCPP/TDCIPP、TDBP/TDBPP、TPhP/TPHP |
| prenatal exposure to Organophosphate Flame Retardants (OPFRs) at second trimester | 22-26 gestational weeks | Maternal serum levels of Organophosphate Flame Retardants (OPFRs) comprising 9 variants: TEP、TBP、TBEP/TBOEP、TPrP、TCEP、TCPP/TCIPP、TDCPP/TDCIPP、TDBP/TDBPP、TPhP/TPHP |
| prenatal exposure to Organophosphate Flame Retardants (OPFRs) at third trimester | 34-36 gestational weeks | Maternal serum levels of Organophosphate Flame Retardants (OPFRs) comprising 9 variants: TEP、TBP、TBEP/TBOEP、TPrP、TCEP、TCPP/TCIPP、TDCPP/TDCIPP、TDBP/TDBPP、TPhP/TPHP |
| Organophosphate Flame Retardants (OPFRs) in Umbilical cord whole blood | at delivery | Umbilical cord whole blood levels of PFDoDA, PFTrDA, PFHpDA, PFBS, PFPeS, PFHxS, PFOS, and PFDS |
| Umbilical cord serum Organophosphate Flame Retardants (OPFRs) | at delivery | Umbilical cord serum levels of PFDoDA, PFTrDA, PFHpDA, PFBS, PFPeS, PFHxS, PFOS, and PFDS |
| Infant skin barrier function (Transepidermal Water Loss, TEWL） | infant 24-48 hours | TEWL will be evaluated by the device of Multi Probe Adapter 4. |
| Infant skin barrier function (skin surface pH) | infant 24-48 hours | Skin pH will be evaluated by the device of Multi Probe Adapter 4. |
| Infant skin barrier function (Stratum corneum hydration, SCH) | infant 24-48 hours | SCH will be evaluated by the device of Multi Probe Adapter 4. |
Countries
China
Contacts
PRINCIPAL_INVESTIGATORYing Ye, MD,PhD
Children's Hospital of Fudan University Shanghai, China, 201102
Outcome results
None listed